DYN
Price
$12.38
Change
-$0.12 (-0.96%)
Updated
Aug 15 closing price
Capitalization
1.76B
75 days until earnings call
RNA
Price
$46.47
Change
+$0.40 (+0.87%)
Updated
Aug 15 closing price
Capitalization
5.98B
87 days until earnings call
Interact to see
Advertisement

DYN vs RNA

Header iconDYN vs RNA Comparison
Open Charts DYN vs RNABanner chart's image
Dyne Therapeutics
Price$12.38
Change-$0.12 (-0.96%)
Volume$1.93M
Capitalization1.76B
Avidity Biosciences
Price$46.47
Change+$0.40 (+0.87%)
Volume$2.81M
Capitalization5.98B
DYN vs RNA Comparison Chart in %
Loading...
DYN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DYN vs. RNA commentary
Aug 16, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DYN is a Hold and RNA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 16, 2025
Stock price -- (DYN: $12.38 vs. RNA: $46.47)
Brand notoriety: DYN and RNA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DYN: 60% vs. RNA: 93%
Market capitalization -- DYN: $1.76B vs. RNA: $5.98B
DYN [@Biotechnology] is valued at $1.76B. RNA’s [@Biotechnology] market capitalization is $5.98B. The market cap for tickers in the [@Biotechnology] industry ranges from $100.71B to $0. The average market capitalization across the [@Biotechnology] industry is $1.88B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DYN’s FA Score shows that 0 FA rating(s) are green whileRNA’s FA Score has 0 green FA rating(s).

  • DYN’s FA Score: 0 green, 5 red.
  • RNA’s FA Score: 0 green, 5 red.
According to our system of comparison, DYN is a better buy in the long-term than RNA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DYN’s TA Score shows that 6 TA indicator(s) are bullish while RNA’s TA Score has 4 bullish TA indicator(s).

  • DYN’s TA Score: 6 bullish, 4 bearish.
  • RNA’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, DYN is a better buy in the short-term than RNA.

Price Growth

DYN (@Biotechnology) experienced а +10.93% price change this week, while RNA (@Biotechnology) price change was +0.39% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +9.90%. For the same industry, the average monthly price growth was +26.70%, and the average quarterly price growth was +20.91%.

Reported Earning Dates

DYN is expected to report earnings on Oct 30, 2025.

RNA is expected to report earnings on Nov 11, 2025.

Industries' Descriptions

@Biotechnology (+9.90% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RNA($5.98B) has a higher market cap than DYN($1.76B). RNA YTD gains are higher at: 59.801 vs. DYN (-47.453). RNA (-430.35M) and DYN (-437.37M) have comparable annual earnings (EBITDA) . RNA has more cash in the bank: 1.38B vs. DYN (684M). RNA has less debt than DYN: RNA (5.97M) vs DYN (121M). RNA has higher revenues than DYN: RNA (8.93M) vs DYN (0).
DYNRNADYN / RNA
Capitalization1.76B5.98B29%
EBITDA-437.37M-430.35M102%
Gain YTD-47.45359.801-79%
P/E RatioN/AN/A-
Revenue08.93M-
Total Cash684M1.38B50%
Total Debt121M5.97M2,025%
TECHNICAL ANALYSIS
Technical Analysis
DYNRNA
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
Momentum
ODDS (%)
Bullish Trend 1 day ago
80%
N/A
MACD
ODDS (%)
Bullish Trend 1 day ago
83%
N/A
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 1 day ago
86%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 1 day ago
88%
Advances
ODDS (%)
Bullish Trend 3 days ago
85%
Bullish Trend 11 days ago
85%
Declines
ODDS (%)
Bearish Trend 9 days ago
88%
Bearish Trend 3 days ago
86%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
82%
Aroon
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
DYN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MBCSX26.20N/A
N/A
MassMutual Blue Chip Growth R5
SVTAX11.25N/A
N/A
SEI Global Managed Volatility F (SIMT)
MLMIX23.72N/A
N/A
Morgan Stanley Instl Global Core I
FLCOX19.56N/A
N/A
Fidelity Large Cap Value Index
LGCYX19.62N/A
N/A
Lord Abbett Global Equity I

DYN and

Correlation & Price change

A.I.dvisor indicates that over the last year, DYN has been loosely correlated with RNA. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if DYN jumps, then RNA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DYN
1D Price
Change %
DYN100%
-0.96%
RNA - DYN
57%
Loosely correlated
+0.87%
CRNX - DYN
54%
Loosely correlated
+3.47%
SYRE - DYN
52%
Loosely correlated
+0.53%
XNCR - DYN
52%
Loosely correlated
+0.39%
IDYA - DYN
51%
Loosely correlated
-0.16%
More

RNA and

Correlation & Price change

A.I.dvisor indicates that over the last year, RNA has been loosely correlated with DYN. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if RNA jumps, then DYN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RNA
1D Price
Change %
RNA100%
+0.87%
DYN - RNA
57%
Loosely correlated
-0.96%
ACLX - RNA
57%
Loosely correlated
+3.09%
OCUL - RNA
53%
Loosely correlated
-0.24%
BEAM - RNA
49%
Loosely correlated
+1.08%
IDYA - RNA
48%
Loosely correlated
-0.16%
More